Key facts
- This page summarizes Glenn Dubin's Form 4 filing for C4 Therapeutics, Inc. (CCCC).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Apr 2024, 16:34.
Glenn Dubin - 01 Apr 2024 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)
- Reporting relationship
- Director
- Issuer ticker
- CCCC
- Reported as of
- 01 Apr 2024
- Net transaction value
- +$11,000
- SEC form
- 4
- Accepted by SEC
- 02 Apr 2024, 16:34:29 UTC
- Prior SEC filing
- 03 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jolie M. Siegel, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Glenn Dubin filed Form 4 for C4 Therapeutics, Inc. (CCCC) on 02 Apr 2024.
Change
- Previous filing in this sequence was filed on 03 Jan 2024.
- Current net transaction value: +$11,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CCCC
transaction
Common Stock
Award
- Transaction value
- $11,000
- Shares
- +1,358
- Change %
- +6.6%
- Price
- $8.10
- Shares after
- 22,075
- Date
- 01 Apr 2024
- Ownership
- Direct
- Footnotes
- F1, F2
CCCC
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 770,607
- Date
- 01 Apr 2024
- Ownership
- By DF Investment Partners LLC
- Footnotes
- F3
CCCC
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,000
- Date
- 01 Apr 2024
- Ownership
- By G&E Dubin Family Foundation
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
Footnote F2
The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2024.
Footnote F3
Shares held directly by DF Investment Partners LLC ("DFIP"). The Reporting Person serves as managing member of DFIP and may be deemed to exercise voting and investment power over the shares held by DFIP. The Reporting Person disclaims beneficial ownership of the shares held by DFIP except to the extent of his pecuniary interest therein.
Footnote F4
Shares held directly by G&E Dubin Family Foundation. The Reporting Person may be deemed to exercise voting and investment power over the shares held by G&E Dubin Family Foundation and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.